Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma
Clinical trial NCT05831891 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05831891
- Sponsor
- RenJi Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2026-07-31
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.